OBJECTIVES: WHO recommends HIV viral load (VL) testing 6 months after antiretroviral therapy (ART) initiation and every 12 months thereafter, but cost prohibits routine, universal VL testing in many developing countries. We sought to devise a targeted approach to routine VL monitoring that could reduce cost and identify those at low risk for virologic failure (VF). METHODS: We analysed screening data from a clinical trial enrolling adults on ART in Malawi. We identified risk factors associated with VF and employed the Knill-Jones method to assign summary score identifying persons at lower risk for VF. RESULTS: Among 957 adults, prevalence of VF was 9.4%. Factors independently associated with VF included age <38 years (OR 3.44, 95% CI 2.01-5.89), ART duration >2.5 years (OR 2.98, 95% CI 1.79-4.96), ART adherence <95% (OR 1.76, 95% CI 1.06-2.94), CD4 count <200 cells/μl (OR 5.94, 95% CI 3.27-10.78), haemoglobin <13 g/dl (OR 2.76, 95% CI 1.70-4.50) and CD8 count >885 cells/μl (OR 2.10, 95% CI 1.28-3.44). Our VF prediction summary score included all factors above except CD8 count and was fairly accurate with validated area under receiver operating characteristic curve of 0.76. Implementation could reduce VL testing by 65%. CONCLUSION: A simple score incorporating age, ART duration and adherence, and CD4 count can accurately identify adults at low risk for VF in a sub-Saharan African setting. In areas with high ART utilisation and limited VL testing capacity, a targeted approach could optimise routine VL monitoring while identifying adults in need of alternate ART regimens.
OBJECTIVES: WHO recommends HIV viral load (VL) testing 6 months after antiretroviral therapy (ART) initiation and every 12 months thereafter, but cost prohibits routine, universal VL testing in many developing countries. We sought to devise a targeted approach to routine VL monitoring that could reduce cost and identify those at low risk for virologic failure (VF). METHODS: We analysed screening data from a clinical trial enrolling adults on ART in Malawi. We identified risk factors associated with VF and employed the Knill-Jones method to assign summary score identifying persons at lower risk for VF. RESULTS: Among 957 adults, prevalence of VF was 9.4%. Factors independently associated with VF included age <38 years (OR 3.44, 95% CI 2.01-5.89), ART duration >2.5 years (OR 2.98, 95% CI 1.79-4.96), ART adherence <95% (OR 1.76, 95% CI 1.06-2.94), CD4 count <200 cells/μl (OR 5.94, 95% CI 3.27-10.78), haemoglobin <13 g/dl (OR 2.76, 95% CI 1.70-4.50) and CD8 count >885 cells/μl (OR 2.10, 95% CI 1.28-3.44). Our VF prediction summary score included all factors above except CD8 count and was fairly accurate with validated area under receiver operating characteristic curve of 0.76. Implementation could reduce VL testing by 65%. CONCLUSION: A simple score incorporating age, ART duration and adherence, and CD4 count can accurately identify adults at low risk for VF in a sub-Saharan African setting. In areas with high ART utilisation and limited VL testing capacity, a targeted approach could optimise routine VL monitoring while identifying adults in need of alternate ART regimens.
Authors: Rupa Kanapathipillai; Megan McGuire; Robert Mogha; Elisabeth Szumilin; Annette Heinzelmann; Mar Pujades-Rodríguez Journal: Trop Med Int Health Date: 2011-09-01 Impact factor: 2.622
Authors: David M Moore; Anna Awor; Robert Downing; Jonathan Kaplan; Julio S G Montaner; John Hancock; Willy Were; Jonathan Mermin Journal: J Acquir Immune Defic Syndr Date: 2008-12-15 Impact factor: 3.731
Authors: Shirley Lecher; Dennis Ellenberger; Andrea A Kim; Peter N Fonjungo; Simon Agolory; Marie Yolande Borget; Laura Broyles; Sergio Carmona; Geoffrey Chipungu; Kevin M De Cock; Varough Deyde; Marie Downer; Sundeep Gupta; Jonathan E Kaplan; Charles Kiyaga; Nancy Knight; William MacLeod; Boniface Makumbi; Hellen Muttai; Christina Mwangi; Jane W Mwangi; Michael Mwasekaga; Lucy W Ng'Ang'A; Yogan Pillay; Abdoulaye Sarr; Souleymane Sawadogo; Daniel Singer; Wendy Stevens; Christiane Adje Toure; John Nkengasong Journal: MMWR Morb Mortal Wkly Rep Date: 2015-11-27 Impact factor: 17.586
Authors: Matthew B Laurens; Randy G Mungwira; Osward M Nyirenda; Titus H Divala; Maxwell Kanjala; Francis Muwalo; Felix A Mkandawire; Lufina Tsirizani; Wongani Nyangulu; Edson Mwinjiwa; Terrie E Taylor; Jane Mallewa; William C Blackwelder; Christopher V Plowe; Miriam K Laufer; Joep J van Oosterhout Journal: Trials Date: 2016-07-18 Impact factor: 2.279
Authors: Janne Estill; Matthias Egger; Leigh F Johnson; Thomas Gsponer; Gilles Wandeler; Mary-Ann Davies; Andrew Boulle; Robin Wood; Daniela Garone; Jeffrey S A Stringer; Timothy B Hallett; Olivia Keiser Journal: PLoS One Date: 2013-02-28 Impact factor: 3.240
Authors: Pamela M Murnane; James Ayieko; Eric Vittinghoff; Monica Gandhi; Chaplain Katumbi; Beteniko Milala; Catherine Nakaye; Peter Kanda; Dhayendre Moodley; Mandisa E Nyati; Amy J Loftis; Mary G Fowler; Pat Flynn; Judith S Currier; Craig R Cohen Journal: J Acquir Immune Defic Syndr Date: 2021-12-15 Impact factor: 3.771
Authors: Todd M Pollack; Hao T Duong; Thuy T Pham; Thang D Nguyen; Howard Libman; Long Ngo; James H McMahon; Julian H Elliott; Cuong D Do; Donn J Colby Journal: J Int AIDS Soc Date: 2019-03 Impact factor: 5.396
Authors: Trudy Tholakele Mhlanga; Richard Makurumidze; Bart K M Jacobs; Tom Decroo; Emma Govere; Hilda Bara; Prosper Chonzi; Ngwarai Sithole; Tsitsi Apollo; Wim Van Damme; Simbarashe Rusakaniko; Lutgarde Lynen Journal: AIDS Res Ther Date: 2022-07-09 Impact factor: 2.846